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ORIGINAL RESEARCH
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SUMMARY
Female mice lacking ATRX in the pancreas have increased
sensitivity to pancreatic cancer, whereas male mice without
ATRX are protected. This study identiﬁes such susceptibility
in pancreatic cancer and highlights the need for sex-speciﬁc
approaches in cancer treatment.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is
the third leading cause of cancer death in North America,
accounting for >30,000 deaths annually. Although somatic
activating mutations in KRAS appear in 97% of PDAC patients,
additional factors are required to initiate PDAC. Because
mutations in genes encoding chromatin remodelling proteins
have been implicated in KRAS-mediated PDAC, we investi-
gated whether loss of chromatin remodeler ɑ-thalassemia,
mental-retardation, X-linked (ATRX) affects oncogenic KRAS’s
ability to promote PDAC. ATRX affects DNA replication, repair,
and gene expression and is implicated in other cancers
including glioblastomas and pancreatic neuroendocrine
tumors. The hypothesis was that deletion of Atrx in pancreatic
acinar cells will increase susceptibility to injury and oncogenic
KRAS.
METHODS: Mice allowing conditional loss of Atrx within pancre-
atic acinar cells were examined after induction of recurrent
cerulein-induced pancreatitis or oncogenic KRAS (KRASG12D). His-
tologic, biochemical, and molecular analysis examined pancreatic
pathologies up to 2 months after induction of Atrx deletion.
RESULTS: Mice lacking Atrx showed more progressive damage,
inﬂammation, and acinar-to-duct cell metaplasia in response to
injury relative to wild-type mice. In combination with KRASG12D,
Atrx-deﬁcient acinar cells showed increasedﬁbrosis, inﬂammation,
progression to acinar-to-duct cell metaplasia, and pre-cancerous
lesions relative to mice expressing only KRASG12D. This sensi-
tivity appears only in female mice, mimicking a signiﬁcant preva-
lence of ATRXmutations in human female PDAC patients.
CONCLUSIONS: Our results indicate the absence of ATRX
increases sensitivity to injury and oncogenic KRAS only in
female mice. This is an instance of a sex-speciﬁc mutation that
enhances oncogenic KRAS’s ability to promote pancreatic
intraepithelial lesion formation. (Cell Mol Gastroenterol Hepatol
2019;7:93–113; https://doi.org/10.1016/j.jcmgh.2018.09.004)
Keywords: Epigenetics; Pancreatic Ductal Adenocarcinoma;
MIST1; SOX9.
See editorial on page 233.
Pancreatic ductal adenocarcinoma (PDAC) is the thirdleading cause of cancer-related death in North
America, with a 5-year survival rate of w9% (Pancreatic
Cancer Facts, PANCAN). PDAC is characterized by increased
genomic instability,1 a poor response to chemotherapeutic
intervention, and often diagnosed at later stages because of
a lack of clinical symptoms and poor diagnostic markers
even for susceptible populations. During the last 10 years,
elegant lineage tracing studies identiﬁed acinar cells as the
cell of origin in many PDAC cases.2–4 In these cases, the
initiating events include acinar-to-duct cell metaplasia
(ADM), in which mature acinar cells transiently revert to a
pancreatic progenitor-like state, increasing the potential
for progression to neoplastic lesions termed pancreatic
intraepithelial lesions (PanINs) and PDAC.2,5
Mutations in KRAS that lead to a constitutively active
form of the protein are a hallmark of PDAC, present in 97%
of cases.3 However, the constitutive activation of KRAS alone
appears to be insufﬁcient to drive PDAC progression, and
additional acquired mutations and/or pancreatic injury are
required.1,6,7 Recent molecular characterization of PDAC
tumors has identiﬁed 4 subtypes for PDAC and mutations
that deﬁne 10 pathways commonly affected in these tumors.
In addition to identifying RAS and NOTCH signaling as key
oncogenic pathways, somatic mutations in genes involved in
chromatin remodeling and SWI/SNF function were identi-
ﬁed.8 Studies using genetically modiﬁed mouse strains
harboring null alleles for the chromatin remodeling proteins
brahma-related gene 19 or B-cell speciﬁc Moloney virus
insertion site 110 increased and decreased, respectively,
the ability for oncogenic KRAS to promote PDAC progres-
sion. These studies conﬁrm the importance of maintaining
chromosome organization/integrity in preventing KRAS-
mediated oncogenic progression. Our goal was to explore
the idea that other components that contribute to SWI/SNF
function and genome integrity may be functionally linked to
oncogenic KRAS activity in promoting PDAC.
ATRX (ɑ-thalassemia, mental-retardation, X-linked) is a
member of the SWI/SNF family of proteins and interacts
with death associated protein 6 (DAXX) to maintain or
remodel appropriate nucleosome organization within the
genome.11,12 In addition to its role in chromatin remodeling,
studies have identiﬁed roles for ATRX in maintaining
genomic stability,13 maintaining proper DNA replication and
repair,14 and affecting gene expression.15 It has been pro-
posed that ATRX-dependent deposition of histone variant
H3.3 prevents the formation of alternative DNA structures
during replication, allowing for proper facilitation of the
replicative process.15,16 Complete loss of ATRX function
during development is lethal,17 but hypomorphic ATRX
mutations are the underlying cause for ATRX syndrome, a
developmental disorder in males involving signiﬁcant
cognitive impairment, facial abnormalities, and development
of ɑ-thalassemia.18 More recently, somatic mutations in ATRX
have been identiﬁed in a number of cancers including glio-
blastomas and pancreatic neuroendocrine tumors.19–22
To date, the role of ATRX in the adult pancreas or PDAC has
not been examined. Therefore, we investigated the effect of
ATRX deletion on pancreatic injury and oncogenic KRAS-
mediated PDAC progression. We generated mouse lines in
which exon 18 of the mouse ATRX gene could be conditionally
deleted in pancreatic acinar cells on its own or in combination
with activation of oncogenic KRAS. Our results showed
that loss of ATRX alters the response to recurrent pancreatic
injury, suggesting a role for ATRX in the repair and regenera-
tion of acinar tissue after pancreatic insult. Furthermore,
combination of Atrx deletion with oncogenic KRAS activation
signiﬁcantly enhanced pancreatic damage within 2 months
relative to oncogenic KRAS alone. Surprisingly, this ability to
sensitize the pancreatic acinar cells to the oncogenic action of
mutated KRASwas observed exclusively in femalemice. These
results indicate that ATRX loss cooperateswith activatedKRAS
to promote pancreatic disease in a sex-speciﬁc manner.
Results
To determine whether ATRX deletion affected the
phenotype of mature acinar cells, AtrxﬂD18 mice23 were
mated to mice expressing creERT from the Mist1 locus
(Mist1creERT; Figure 1A), allowing for acinar-speciﬁc deletion
in the pancreas.24,25 Deletion of exon 18 results in complete
loss of ATRX, likely because of mRNA instability.23 A shorter
isoform of ATRX may still be expressed, but this truncated
form lacks the SWI/SNF domain.26 Tamoxifen was admin-
istered to 2- to 4-month-old mice, and ATRX accumulation
was assessed 7, 35, or 60 days after dosing (Figure 1B and C).
Immunoﬂuorescence analysis conﬁrmed 98% of acinar
cells were ATRX-negative at all time points, demonstrating
efﬁcient Atrx deletion and indicating mature acinar cells
do not require ATRX for maintained viability (Figure 1C).
Co-immunoﬂuorescence for ATRX and insulin and identiﬁ-
cation of duct nuclei based on morphology conﬁrmed Atrx
deletion speciﬁcally in acinar cells (Figure 1D).
Histologic analysis showed no obvious phenotypes
regarding disorganization of acinar cells or injury/
inﬂammation (Figure 2A), although intralobular adipocytes
were observed at a higher frequency in Mist1creERT/þ
AtrxﬂD18 mice. Because loss of ATRX showed limited effects
on overall pancreatic morphology, we focused speciﬁcally on
the 60-day time point to determine whether any phenotypes
occurred in response to loss of ATRX. Immunoﬂuorescence
analysis for proliferative markers Ki67 (Figure 2B) and pH3
Abbreviations used in this paper: ADM, acinar-to-duct cell metaplasia;
ANOVA, analysis of variance; ATRX, ɑ-thalassemia, mental-
retardation, X-linked; CIP, cerulein induced pancreatitis; CPA,
carboxypeptidase; DAXX, death associated protein 6; ds, double
stranded; EZH2, Enhancer of Zeste Homologue 2, MKA, Mist1creERT/
DKrasLSL-G12D/DAtrxﬂD18; PanIN, pancreatic intraepithelial lesion;
PDAC, pancreatic ductal adenocarcinoma; WT, wild-type.
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(data not shown) or TUNEL analysis (Figure 2C) revealed
increased numbers of proliferating and apoptotic cells after
ATRX deletion. Because ATRX is involved in double stranded
(ds) DNA repair,14,27 we examined gH2AX accumulation, a
marker for unresolved dsDNA breaks. Mist1creERT/þAtrxﬂD18
pancreatic tissue showed an increase in the number of cells
accumulating gH2AX (Figure 2D), suggesting loss of ATRX
leads to an inability to resolve dsDNA breaks. These results
suggest that short-term loss of ATRX in pancreatic acini has
no overt consequences on pancreatic morphology but may
increase susceptibility to events that require intact DNA
repair pathways, such as pancreatic injury.
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To examine this possibility,Mist1creERT/þ andMist1creERT/þ
AtrxﬂD18 mice were subjected to recurrent pancreatic injury
for 11 days and allowed to recover for 3 days. We chose a
mild dosing regimen so damage in control mice would be
limited. No signiﬁcant differences were observed between
Mist1creERT/þ and Mist1creERT/þAtrxﬂD18 mice based on body
weight, behavior, or gross tissue morphology 3 days after
cessation of cerulein (data not shown). However, histologic
analysis showed marked differences between the 2 geno-
types in response to cerulein treatment. As expected,
cerulein-treated Mist1creERT/þmice show intra-acinar edema
but no evidence of inﬂammation or ﬁbrosis (Figure 3A),
likely because of the mild nature of the cerulein treatment.
Conversely, cerulein-treated Mist1creERT/þAtrxﬂD18 mice
showed increased damage (Figure 3A) and ﬁbrosis in female
Mist1creERT/þAtrxﬂD18 mice relative to controls (Figure 3B
and C), as indicated by H&E and trichrome histology,
respectively. This enhanced cellular damage was further
conﬁrmed by the strong immunoﬂuorescence signal for F4/
80 antigen that was indicative of extensive macrophage
inﬁltration in Mist1creERT/þAtrxﬂD18 mice relative to controls
(Figure 3D). Quantiﬁcation of the tissue damage conﬁrmed
increased sensitivity to recurrent cerulein induced pancre-
atitis (CIP) and indicated that female Mist1creERT/þAtrxﬂD18
mice are clearly more sensitive than male mice to these
effects (Figure 3C, Table 2). Whereas analysis of acinar cell
death by cleaved caspase-3 showed no difference between
genotypes (Figure 4A), notably enhanced cell turnover
based on cleaved caspase-3 (Figure 4B) or proliferative
capacity by Ki67 staining (Figure 5E) was observed in
Mist1creERT/þAtrxﬂD18 pancreata in areas showing classic
features of ADM after CIP. No such areas of ADM were
observed in Mist1creERT/þ mice (Table 2).
Tissue histology also revealed a notable increase in ADM
in Mist1creERT/þAtrxﬂD18 tissue based on the appearance of
tubular complexes (Figure 3B). Western blot analysis
(Figure 5A) for mature acinar cell markers amylase and
pro-carboxypeptidase (CPA) conﬁrmed a different response
to recurrent CIP in Mist1creERT/þAtrxﬂD18 mice. Cerulein-
treated Mist1creERT/þ mice exhibited increased accumula-
tion of amylase and CPA compared with saline-treated
controls, which was indicative of a regenerative response
to injury. However, Mist1creERT/þAtrxﬂD18 mice did not show
this recovery from injury (Figure 5A). This difference in
enzyme accumulation was not due to increased release of
enzymes in response to injury because circulating levels of
amylase were not signiﬁcantly different between genotypes
(Figure 5B). Immunohistochemical analysis conﬁrmed
decreased CPA accumulation in both putative ADM as well
as surrounding acinar cells (Figure 5C). Surprisingly, this
decrease in CPA accumulation appeared to be more dra-
matic in cerulein-treated female Mist1creERT/þAtrxﬂD18 mice.
Acini (delineated by a dotted line) show limited CPA accu-
mulation in tissue sections from female mice (Figure 5C).
We next examined expression of the progenitor/duct cell
marker SOX9, a transcription factor that increases during
regeneration and is required for ADM.4 In adult pancreatic
tissue, SOX9 is expressed only in a subset of duct and
centroacinar cells,4,28 which we conﬁrmed by immunoﬂuo-
rescence on sections from saline-treated and cerulein-
treated Mist1creERT/þ mice (Figure 5D and E). Conversely,
increased SOX9 nuclear accumulation was observed in
female and male Mist1creERT/þAtrxﬂD18 pancreatic tissue
speciﬁcally after CIP treatment (Figure 5D), accumulating in
ADM and some acinar cells (Figure 5D and E). Taken
together, these data suggest loss of ATRX increased the
sensitivity of acinar cells to recurrent cerulein exposure.
These ﬁndings suggest that Mist1creERT/þAtrxﬂD18 mice
will have increased susceptibility to oncogenic properties of
mutated KRAS, because maintenance of the acinar phenotype
constrains KRAS-induced transformation.5,9,29 Therefore, we
next introduced an inducible form of oncogenic KRAS
(KrasLSL-G12D/þ) into the Mist1creERT/þAtrxﬂD18 genotype
(Mist1creERT/þKrasLSL-G12D/þAtrxﬂD18 hereafter referred to as
MKA; Figure 6A). Cre-mediated induction of KRASG12D þ/-
deletion of Atrx was initiated in 2- to 4-month-old congenic
Mist1creERT/þ,Mist1creERT/þAtrxﬂD18,Mist1creERT/þKrasLSL-G12D/þ,
and MKA mice (Figure 6B), and acinar cell–speciﬁc loss of
ATRX was conﬁrmed by immunohistochemistry (Figure 6C).
No signiﬁcant differences were observed in body weight
between groups during the course of the experiment
(Figure 6D), and assessment of serum amylase levels at the
time of death revealed no differences between genotypes
(Figure 6E). Because of the presence of oral squamous pap-
illoma tumors in KRASG12D-expressing mice, the experiment
was terminated at 60 days after tamoxifen administration
(data not shown). Gross morphologic examination revealed
enlarged spleens in female Mist1creERT/þKrasLSL-G12D/þ and
MKA mice (Figure 7).
Histologic examination revealed normal pancreatic
morphology in Mist1creERT/þ and Mist1creERT/þAtrxﬂD18 mice
(Figure 8A). Mist1creERT/þKrasLSL-G12D/þ mice also showed
typical pancreatic morphology for the most part, with a few
instances of ADM or PanINs (Figure 8A). This is consistent
with previous reports that activation of oncogenic KRASG12D
in mature acinar cells was insufﬁcient on its own to cause
Figure 1. (See previous page). Loss of ATRX in the pancreas is speciﬁc to acinar cells. (A) Schematic of Atrx deﬁcient
model. AtrxﬂD18 mice carrying loxP sites that ﬂank exon 18. CreERT is expressed from the Mist1 promoter. On tamoxifen
administration to Mist1creERT/þAtrxﬂD18 mice, cre recombinase becomes localized to the nucleus and produces deletion of
exon 18 of the Atrx gene. This leads to degradation of full-length Atrx mRNA. (B) Immunoﬂuorescence for ATRX in pancreatic
tissue from Mist1creERT/þ (WT) mice 7, 35, or 60 days after tamoxifen gavage in Mist1creERT/þAtrxﬂD18 mice (AtrxﬂD18). White
arrows indicate residual ATRX expression. Magniﬁcation bars ¼ 25 mm. (C) Atrx deletion efﬁciency was quantiﬁed as the
percentage of acinar cells lacking ATRX (n ¼ 3 for all groups). (D) Localization of insulin (green) and ATRX (red) by
co-immunoﬂuorescence (IF) demonstrates acinar-speciﬁc knockout of ATRX expression inMist1creERT/þAtrxﬂD18 mice 20 days
after tamoxifen treatment.White arrows indicate ATRX expression in pancreatic duct cells. Sections were counterstained with
DAPI to reveal nuclei. Magniﬁcation bar ¼ 50 mm.
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widespread pancreatic damage.3 Conversely, MKA mice
demonstrated a variable phenotype based on sex
(Figure 8A). Male MKA mice (n ¼ 10) appeared phenotyp-
ically normal with negligible PanIN formation and few
pockets of ﬁbrosis relative to Mist1creERT/þKrasLSL-G12D/þ
mice. Conversely, all female MKA mice (n ¼ 6) developed
PanINs and ﬁbrosis, with some mice displaying extensive
inﬂammation and ﬁbrosis, along with disruptions in acinar
cell organization consistent with a chronic pancreatitis
phenotype (Figure 8A). Trichrome staining conﬁrmed
increased ﬁbrosis only in female MKA pancreatic tissue
relative to Mist1creERT/þKrasLSL-G12D/þ mice (Figure 9A), and
Alcian blue histology conﬁrmed increases in neoplastic
PanIN lesions (Figure 9B). The tissue showed signiﬁcant
variability in ﬁbrosis between mice in both MKA and
Mist1creERT/þKrasLSL-G12D/þ cohorts (Figure 9C), although
female MKA mice in general had increased damage
(MKA ¼ 15.2% ± 9.2% damaged area vs Mist1creERT/þ
KrasLSL-G12D/þ ¼ 5.0% ± 1.6%), whereas male MKAmice had
decreased damage (MKA ¼ 0.2% ± 0.2% vs Mist1creERT/þ
KrasLSL-G12D/þ ¼ 5.8% ± 3.8%). On the basis of a 2-way
ANOVA, no signiﬁcant differences were observed between
any group regarding damaged (ie, lesion) area. However,
quantiﬁcation of lesion type (Figure 9D) indicated signiﬁ-
cantly more pre-cancerous lesions develop in female MKA
mice relative to all groups exceptMist1creERT/þKrasLSL-G12D/þ
male mice. Quantiﬁcation of overall pancreatic ﬁbrosis,
inﬂammation, and ADM, as described earlier, conﬁrmed
increased injury in MKA females relative to Mist1creERT/þ
KrasLSL-G12D/þ counterparts (Table 3).
To assess PanIN formation within Mist1creERT/þKrasLSL-
G12D/þ and MKA pancreatic tissue, the percentage of
pancreatic lobules containing at least one instance of each
lesion type (ranging from ADM to PanIN3) was quantiﬁed
on H&E stained sections (Figure 8B) and statistically
compared by 2-way ANOVAs (Table 4). MKA female mice
had signiﬁcantly fewer lobules consisting only of normal
acini relative to all other groups (Table 4, P < .05). Whereas
both Mist1creERT/þKrasLSL-G12D/þ and MKA mice exhibited
ADM, the incidence of PanIN1 in female MKA mice was
2.5-fold higher (16.21% ± 8.3% of lobules; n ¼ 10) relative
to female Mist1creERT/þKrasLSL-G12D/þ mice (6.52% ± 3.5%;
n ¼ 6), and female MKA mice contained signiﬁcantly more
lobules with PanIN2 lesions than all other genotypes and
sexes (Figure 8B, Table 4; P < .01). Interestingly, histologic
analysis of male MKA mice revealed no PanIN1 or PanIN2
lesions (Figure 8B, Table 4).
To determine whether presumptive ADM and PanINs
were arising from ATRX null acinar cells, we examined the
expression of transcription factors involved in ADM. SOX9
(Figure 10A and B) and PDX1 (data not shown)
accumulation was assessed by immunoﬂuorescence and
immunohistochemistry, respectively. As observed earlier,
no SOX9þ acinar cells were observed in Mist1creERT/þ
and Mist1creERT/þAtrxﬂD18 mice. Similarly, Mist1creERT/þ
KrasLSL-G12D/þ tissue was devoid of SOX9þ acinar cells,
although pockets of putative SOX9þ ADM were observed
(Figure 10A). Whereas male MKA mice showed few SOX9-
expressing cells, SOX9þ cells and ADM were readily
apparent in female MKA mice (Figure 10A and B). This
widespread SOX9 accumulation in both ADM and acinar
cells adjacent to areas of damage suggested SOX9 expres-
sion precedes ADM, which is in support of previous studies
indicating SOX9 expression is required for ADM. Similar
increases for PDX1 were observed in female MKA tissue,
with PDX1þ cells readily observed in ADM and PanINs (data
not shown) compared with all other genotypes. In many
cases, cells within ADMs and PanIN lesions also stained for
Ki67 (Figure 10B), indicating an increase in proliferation in
these areas. Quantiﬁcation of Ki67þ acinar cells showed no
signiﬁcant difference between genotypes, suggesting that
proliferation likely occurs after ADM (Figure 10C).
This expression pattern of SOX9 suggests normal pro-
gression through ADM in MKA mice but does not indicate
whether ADM arises from ATRX-positive cells. Therefore,
ATRX accumulation was examined to conﬁrm an acinar cell
origin for ADM and PanINs. All presumptive ADM observed
in male Mist1creERT/þKrasLSL-G12D/þ mice tissue was ATRX
positive. Similarly, all ADM and PanINs in female
Mist1creERT/þKrasLSL-G12D/þ tissue contained exclusively
ATRX-positive cells. In Mist1creERT/þKrasLSL-G12D/þAtrxﬂD18/x
female mice, which harbor one transcriptionally active copy
of the Atrx gene, ADM and PanINs contained mixed pop-
ulations of ATRXþ and ATRX– cells. Fifty-nine percent ±
17% of lesions contained at least 1 ATRXþ cell, with the
other 41% ± 17% lesions containing only ATRX-negative
cells (Figure 10D and E). The ATRX– lesions likely arise
from cells in which the non-targeted Atrx gene has been
silenced as part of X chromosome inactivation. Although
some ATRXþ cells were observed in PanINs and ADMs of
MKAmice, the majority of lesions were completely devoid of
ATRX expression in male (82% ± 7%) and female (73% ±
10%) mice. Because ATRX is ubiquitously expressed, the
absence of ATRX in PanINs and ADM suggests the origin of
these lesions in MKA mice as acinar cells.
Finally, to determine whether sex-speciﬁc susceptibility
conferred by the absence of ATRX on KRAS mice translates
to humans, we queried the International Cancer Genome
Consortium (dcc.icgc.org) database for ATRX mutations
(Figure 11). The International Cancer Genome Consortium
database includes whole genome sequence analysis for 729
patients from Australian and Canadian tumor sequencing
Figure 2. (See previous page). Mature acinar cells do not require ATRX for maintenance, but ATRX loss induces low
levels of pancreatic damage. (A) Representative H&E staining of Mist1creERT/þ (WT) and Mist1creERT/þAtrxﬂD18 (AtrxﬂD18)
pancreatic tissue 60 days after last tamoxifen gavage. Intralobular adipocytes are indicated by *. (B–D) Representative images
and quantiﬁcation for (B) Ki67 immunoﬂuorescence (Mist1creERT/þ [WT; n ¼ 4];Mist1creERT/þAtrxﬂD18 [ATRX–; n ¼ 5]), (C) TUNEL
(Mist1creERT/þ, n ¼ 9; Mist1creERT/þAtrxﬂD18, n ¼ 10), or (D) gH2AX IF (Mist1creERT/þ [n ¼ 7]; Mist1creERT/þAtrxﬂD18 [n ¼ 11]) 60
days after tamoxifen treatment.White arrows indicate positive cells. Magniﬁcation bar ¼ 50 mm. Data were assessed by using
two-tailed t test with Tukey post hoc test. Error bars represent means ± standard error; *P < .005.
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studies and consists of 324 female patients (42%) and 405
male patients (53%). Gender was not identiﬁed in 5% of the
patients. Therefore, the proportion of PDAC patients re-
ported as female was 0.44. KRAS mutations were identiﬁed
in 591 patients, with a similar ratio of male (55%) to female
(45%) patients. Two hundred sixty-eight mutations were
observed within the ATRX gene, encompassing 145 (w19%)
PDAC patients, with 68% of ATRX mutations in female
patients. Therefore, the proportion of PDAC patients
carrying ATRX mutations that were female was 0.68. The
difference in proportions is signiﬁcant, c2(1, N ¼ 729) ¼
41.633; P < .00001 (Figure 11B), suggesting ATRX muta-
tions are related to the sex of the patient.
Most ATRX mutations in both sexes are found in non-
coding regions, and the impact on expression is unknown.
However, 8 patients harbor ATRX mutations with a pre-
dicted impact on protein function. All but one of these
mutations occur in female patients, suggesting a sex-speciﬁc
susceptibility in the human patient population. Pancreatic
neuroendocrine and glioblastoma patient populations show
46% and 42% of the identiﬁed ATRX mutations are in
female populations. Conversely, 60% of the ATRX mutations
found in the pediatric brain tumor population occur in
female patients. However, c2 analysis indicates the pro-
portions of ATRX mutations are independent of sex
(Figure 11C and data not shown). Interestingly, mutations
in DAXX, the partner for ATRX in depositing H3.3 variant
histones into chromatin,11,12 are rare in PDAC and show no
sex bias. Other common mutations linked to PDAC, including
P16/CDNK2 (Figure 11A) and SMAD4 (data not shown),
showed no sex bias.
Discussion
Pancreatic ductal adenocarcinoma is currently the third
leading cause of cancer-related deaths in North America
(www.pancan.org). Five-year survival rates have increased
only marginally in the last 30 years because of late stage of
diagnosis and insensitivity to conventional chemothera-
peutics. Therefore, detecting factors that increase sensitivity
of pancreatic tissue to the oncogenic properties of mutated
KRAS is important in identifying alternative therapeutic and
diagnostic options. In this study, we have shown that acinar-
speciﬁc loss of ATRX, a chromatin remodelling protein,
affects the tissue’s response to injury and constitutive
mutant KRAS activity. Using a novel mouse line that allows
for acinar-speciﬁc ablation of Atrx, we show loss of ATRX
increased the sensitivity for pancreatic injury. In addition,
we showed loss of Atrx dramatically enhanced the ability of
oncogenic KRAS to promote precancerous lesions in the
pancreas. Importantly, these effects were observed in a sex-
speciﬁc fashion, with only female mice displaying sensitivity
to loss of ATRX. Our results also suggest that loss of ATRX
may reduce the sensitivity to oncogenic KRAS in male mice.
This is evidence of a sex-speciﬁc susceptibility factor and
suggests stratiﬁcation of PDAC based on their molecular
proﬁle may identify new targets for therapy and diagnosis.
Although we have not deﬁned a role for ATRX in normal
acinar cell physiology, it appears ATRX is dispensable for
maintaining the acinar cell phenotype in the adult. This is
consistent with previous studies that identiﬁed roles for
ATRX only in mitotically active tissue, where loss of ATRX
Figure 3. (See previous page). Loss of ATRX sensitizes acinar tissue to recurrent pancreatic injury 3 days after
cessation of pancreatic injury. (A) H&E staining of saline or cerulein (CIP) treatedMist1creERT/þ (WT) andMist1creERT/þAtrxﬂD18
(AtrxﬂD18) mice. CIP-treated Mist1creERT/þ mice show vacuolation and intra-acinar edema relative to saline-treated mice. CIP-
treated Mist1creERT/þAtrxﬂD18 mice demonstrated increased damage (black arrows) and putative ADM (white arrows) relative to
CIP-treated Mist1creERT/þ mice. Magniﬁcation bar ¼ 50 mm. (B) Trichrome stain of Mist1creERT/þ and Mist1creERT/þAtrxﬂD18
tissue indicating ﬁbrosis. Mist1creERT/þAtrxﬂD18 mice exhibit increased ﬁbrosis (black arrow) and to a greater extent in female
Mist1creERT/þAtrxﬂD18 mice. Magniﬁcation bar ¼ 100 mm. (C) Quantiﬁcation of ﬁbrosis in pancreatic tissue from Mist1creERT/þ
(WT) mice treated with saline (n ¼ 4 female or 3 male) or cerulein (n ¼ 4 female or 5 male) and Mist1creERT/þAtrxﬂD18 (AtrxﬂD18)
mice treated with saline (n ¼ 5 female or 3 male) or cerulein (n ¼ 5 female and male). Male mice are denoted as black symbols
and female mice as red symbols. Data were assessed using 2-way ANOVA with Tukey post hoc test. Error bars represent
means ± standard error. When not considering sex (upper graph), no signiﬁcant differences exist between groups. When sex of
the mouse is considered (lower graph), female CIP-treated Mist1creERT/þAtrxﬂD18 mice are signiﬁcantly different than all groups
(*P < .05 vs all male mouse groups; **P < .01 vs female Mist1creERT/þ and Mist1creERT/þAtrxﬂD18 saline-treated and female
Mist1creERT/þ CIP-treated groups). Individual animals are denoted with black (male) or red (female) markers. (D) Representative
immunoﬂuorescent images of F4/80 accumulation in CIP-treated female Mist1creERT/þ and Mist1creERT/þAtrxﬂD18 tissue
(repeated 3 times). Arrows indicate macrophages. Sections were counterstained with DAPI. Magniﬁcation bar ¼ 70 mm.
Table 1.Histology Grading Criteria
ADM (based on worst
pancreatic lobule)
Fibrosis (based on
trichrome stain)
0 None present 0 None present
1 >10% of lobule 1 <5% of tissue area
2 10%–30% of lobule 2 5%–10% of tissue area
3 30%–50% of lobule 3 10%–20% of tissue area
4 >50% of lobule 4 >20% of tissue area
Inﬂammation
0 None present
1 Focal: small, contained areas
2 Mild: small, slightly diffuse areas
3 Moderate: diffuse areas
4 Severe: diffuse areas, signiﬁcant presence throughout
the tissue
NOTE. Grading of pancreatic lesions: pancreatic lesions
(ranging from ADM to PanIN grade 3) were quantiﬁed and
classiﬁed into the following categories: ADM, PanIN grade 1,
PanIN grade 2, PanIN grade 3, or PDAC based on morpho-
logic characteristics including cell shape (cuboidal or
columnar), presence of mucin accumulation, nuclear atypia,
pseudostratiﬁcation, and papillary or cribriform structure.
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maintains genomic stability and regulates cell cycle pro-
cesses including proper chromosome segregation during
mitosis.14,27 We did observe small, yet signiﬁcant increases
in acinar cell apoptosis, dsDNA damage, and proliferation in
Mist1creERT/þAtrxﬂD18 mice, suggesting during a longer
period of time (>2 months), the absence of ATRX may lead
to more overt damage. Acinar cell division in the adult
rodent pancreas is <2%,30 which is similar to the observed
rates of apoptosis and dsDNA damage. However, targeted
ablation of other factors, including Xbp131 and Pdx1,32
results in rapid loss of acinar tissue, so acinar cell division
is clearly not a prerequisite for development of overt
pancreatic pathologies. Mild damage in acinar tissue with
ATRX loss suggested acinar cells may be sensitive to other
factors known to promote pancreatic pathologies.
When exposed to recurrent cerulein treatment, only
Mist1creERT/þAtrxﬂD18 mice showed ﬁbrosis, inﬂammatory
cell inﬁltration, and regions of ADM, with the effects more
dramatic in female mice. It is unclear whether loss of ATRX
leads to increased damage or if regeneration is impaired in
Mist1creERT/þAtrxﬂD18 mice. Unpublished work from our
laboratory using an acute pancreatitis regimen indicated
similar amounts of damage in control and Mist1creERT/þ
AtrxﬂD18 mice immediately after injury, suggesting loss of
ATRX impairs the regenerative process after injury, and is
consistent with studies in which other chromatin remodel-
ling proteins (EZH233 and BMI110) are required for proper
pancreatic regeneration. It is possible that defects from Atrx
loss become more widespread once injury is induced, and
increased DNA damage and/or replicative defects provide a
barrier to acinar tissue regeneration. However, we found no
differences in apoptosis and proliferation in cerulein-treated
mice, suggesting these are not contributing factors through
which ATRX loss promotes damage.
The combination of Atrx deletion with oncogenic KRAS
activation produced extensive ﬁbrosis and inﬂammation,
pancreatic damage indicative of chronic pancreatitis, as well
as PanIN lesions up to grade 2. In this instance, damage was
exclusive to female mice. Consistent with previous studies,34
we observed minimal ﬁbrosis and PanIN lesions in KRAS
mice that indicate oncogenic KRAS activation in adult mice
required another stimulus, such as chronic pancreatitis, to
produce invasive PDAC. The pancreatic injury observed in
the female MKA mice suggests that chronic pancreatitis
occurs in these mice, and the inﬂammation observed may
contribute to increased susceptibility to active KRAS. Loss of
function mutations in ATRX have been identiﬁed in other
cancer types, most notably those involving up-regulation
of the alternative lengthening of telomeres pathway.13,35
Mutations in ATRX or binding partner DAXX are often
observed in pancreatic neuroendocrine tumors and glio-
blastomas, but neither cancer shows a gender preference
with or without ATRX mutation. Studies examining PDAC
tumors conﬁrmed an absence of alternative lengthening of
telomeres in every case,36 and PDAC is typically character-
ized by telomere attrition.37 Therefore, we suggest that
ATRX is affecting an alternative pathway in PDAC, possibly
in a DAXX-independent manner. ATRX interacts with
enhancer of zeste homologue 2 (EZH2), a member of poly-
comb repressor complex 2, leading to altered gene expres-
sion,38 and loss of EZH2 also increases sensitivity to
oncogenic KRAS.33
The incidence of human PDAC between sexes is rela-
tively equal, with approximately the same number of cases
occurring in men and women (Canadian Cancer Statistics,
2016). Assessment of International Cancer Genomic Con-
sortium database revealed ATRX single nucleotide poly-
morphisms in almost 20% of PDAC cases (145/729),
although most were in non-coding regions of the gene.
However, whether in the coding or non-coding regions,
ATRX mutations had a higher than expected frequency in
female patients, even when taking into consideration that it
is an X-linked gene. Therefore, it is possible that ATRX loss
deﬁnes a unique subtype of PDAC, in which female patients
are more susceptible, or that loss of ATRX function in male
patients does not allow progression through to a PDAC
phenotype. Although we have observed decreased acinar
cell sensitivity to oncogenic KRAS in male mice, female MKA
mice show signiﬁcantly increased progression to PanIN1
and PanIN2 lesions, and the mechanisms underlying the
extensive pancreatic damage speciﬁcally in female MKA
mice are unclear. It is possible that loss of ATRX enhances
KRAS activity and leads to altered hormonal signalling.
Sex hormone receptors, including estrogen receptors, play a
role in the progression of other cancers such as colorectal
cancer.39 However, the Atrx gene is located on the X
Table 2.Morphometric Analysis of Pancreatic Tissue After Recurrent Pancreatic Damage
Male Female
Mist1creERT/þ (5) Mist1creERT/þAtrxﬂD18(5) Mist1creERT/þ (4) Mist1creERT/þAtrxﬂD18 (5)
Fibrosis 0 ± 0 0 ± 0 0 ± 0 1.4 ± 0.51
Inﬂammation 0.2 ± 0.20 1.4 ± 0.25 0.75 ± 0.25 2.4 ± 0.40
ADM 0 ± 0 0.6 ± 0.25 0 ± 0 1.2 ± 0.37
Total 0.2 ± 0.2 2.0 ± 0.45 0.75 ± 0.25 5.0 ± 1.1a
NOTE. (#) indicates n value; see methodology for scoring. Histopathologic assessment of pancreatic damage, as indicated by
3 factors: ﬁbrosis, inﬂammation, and presence of ADM. Scores are represented on a grading scale from 0 to 4. Superscript
letter “a” indicates groups that are statistically different (P < .01). Data were assessed using 2-way ANOVA and Tukey post
hoc test.
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Figure 4.Mist1creERT/DAtrxﬂD18 pancre-
atic tissue shows increased apoptosis
after recurrent CIP treatment. (A) Acinar
cell–speciﬁc cleaved caspase-3
comparing Mist1creERT/þ (WT) and Mis-
t1creERT/þAtrxﬂD18 (AtrxﬂD18) pancreatic
tissue after saline (SAL) or cerulein (CIP)
treatment. Quantiﬁcation in pancreatic
tissue from Mist1creERT/þ (WT) mice
treated with saline (n¼ 4 female or 3 male)
or cerulein (n ¼ 4 female or 5 male) and
Mist1creERT/þAtrxﬂD18 (AtrxﬂD18) mice
treated with saline (n¼ 5 female or 4 male)
or cerulein (n ¼ 5 female and male). Data
were assessed using 2-way ANOVA with
Tukey post hoc test. Error bars represent
means ± standard error. (B) Immunohis-
tochemistry for cleaved caspase-3 in male
and female Mist1creERT/þ (WT) or Mis-
t1creERT/þAtrxﬂD18 pancreatic tissue 3 days
after cessation of cerulein treatment. Ar-
rows indicate apoptotic cells. Magniﬁca-
tion bar ¼ 50 mm.
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chromosome and is a target of X inactivation. Therefore, it
would be expected that female mice heterozygous (AtrxﬂD18/x)
for the mutant Atrx allele would also show similar effects
because approximately half of the acinar cells lose ATRX
expression. Immunohistochemistry for ATRX conﬁrmed that
at least a portion of acinar cells in heterozygous AtrxﬂD18/x
mice did lose ATRX expression (data not shown), but these
mice did not demonstrate increased damage or susceptibility
to oncogenic KRAS. These results suggest complete loss of
ATRX is required for enhanced KRAS activity and pancreatic
damage to occur in female mice. However, such a model also
does not account for decreased sensitivity in male MKA mice.
Figure 5.Mist1creERT/
DAtrxﬂD18 pancreatic tis-
sue shows reduced
regeneration after recur-
rent CIP treatment. Tis-
sue was examined 3 days
after cessation of recurrent
CIP treatment. (A) Western
blot analysis for CPA,
amylase, SOX9, and total
ERK1/2 (tERK1/2; loading
control). Increased accu-
mulation of digestive en-
zymes was observed
speciﬁcally inMist1creERT/þ
(WT) mice, whereas Mis-
t1creERT/þAtrxﬂD18
(AtrxﬂD18) mice did not
demonstrate similar accu-
mulation. (B) Serum
amylase levels in mice (n ¼
3–4 for each group). Data
were assessed by using 2-
way ANOVA with Tukey
post hoc test. Bars repre-
sent mean ± standard er-
ror. No signiﬁcant
difference in body weight
or amylase levels was
observed between geno-
types. (C) Immunohisto-
chemistry for CPA in
Mist1creERT/þ or Mis-
t1creERT/þAtrxﬂD18 mice.
CPA accumulation was
decreased in female Mis-
t1creERT/þAtrxﬂD18 mice
(acinus is indicated by
dotted line). (D) Represen-
tative immunoﬂuores-
cence for SOX9 (green)
expression was increased
in male Mist1creERT/
þAtrxﬂD18 and female Mis-
t1creERT/þAtrxﬂD18 tissue
(white arrows). Magniﬁca-
tion bars ¼ 50 mm. (E)
Higher magniﬁcation im-
ages show SOX9 expres-
sion in duct, putative ADM
(white arrows), and acinar
cell (yellow arrowheads).
Sections were co-stained
for Ki-67 (red arrowheads)
and counterstained with
DAPI.
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Sex-speciﬁc mechanisms could also be explained by a
difference in inﬂammatory response. It is possible that
female AtrxﬂD18/ ﬂD18 mice are more susceptible to factors
promoting inﬂammation. During recurrent pancreatic
injury, AtrxﬂD18/ ﬂD18 mice showed increased inﬂammation
in comparison with male counterparts, resulting in higher
levels of damage. In combination with oncogenic KRAS,
increased inﬂammation in AtrxﬂD18/ ﬂD18 mice may amplify
KRAS activity and activation of downstream pathways,
including MAPK and PI3K-PDK1-Akt signaling, leading to
increased cell survival and proliferation. Accordingly,
increased KRASG12D activity by inﬂammatory cytokines
(nuclear factor kappa B, interleukin 6) has been demon-
strated previously.40,41 The presence of an inﬂammatory
response in female AtrxﬂD18/ ﬂD18 mice, which is not
observed in male AtrxﬂD18/y mice, could lead to increased
damage.
It is also possible that sex-speciﬁc differences exist
regarding the function of SOX9. Previous work suggests
SOX9 is required for initiation of ADM,4 and we show
Figure 6. Induction of oncogenic KRAS with Atrx deletion. (A) Schematic of Atrx-deﬁcient mouse model with oncogenic
KRAS activation. (B) Experimental timeline for tamoxifen gavage in congenic Mist1creERT/þ, Mist1creERT/þAtrxﬂD18, Mist1creERT/
þKrasLSL-G12D/þ, and MKA mice. Names used for each line within the ﬁgures are depicted in bold. (C) Immunohistochemistry
for ATRX in acinar (black arrow) and duct (red arrow) cells of Mist1creERT/þ and Mist1creERT/þAtrxﬂD18 mice, ATRX expression is
limited to islet (open arrow; delineated by dotted line) and duct cells (red arrow). (D) Change in body weight (%) of mice after
Atrx deletion ± oncogenic KRAS activation. Mouse genotypes include Mist1creERT/þ (WT; n ¼ 13), Mist1creERT/þAtrxﬂD18
(AtrxﬂD18; n ¼ 12), Mist1creERT/þKrasLSL-G12D/þ (KrasLSL-G12D/þ; n ¼ 17), and MKA (n ¼ 16). Points are represented as mean
weight ± standard error. (E) Serum amylase levels in WT (n ¼ 7 male or 3 female), AtrxﬂD18 (n ¼ 7 male or 5 female), KrasLSL-
G12D/þ (n ¼ 6 male or 5 female), and MKA (n ¼ 8 male or 6 female) mice 60 days after Atrx deletion ± oncogenic KRAS
activation. Data were assessed using 2-way ANOVA with Tukey post hoc test. Bars represent mean ± standard error.
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increased SOX9 accumulation in female MKA acinar cells
surrounding damage. Increased susceptibility in female
MKA mice could include sex-speciﬁc hormonal or inﬂam-
matory pathways that provoke increased SOX9 expression.
As mentioned, female AtrxﬂD18/ ﬂD18 mice have an ampli-
ﬁed inﬂammatory response, and inﬂammatory signaling
pathways can inﬂuence SOX9 expression during develop-
ment.42 Alternatively, hormonal factors could play a role in
sex-speciﬁc Sox9 regulation. Recently, up-regulation of
estrogen receptor a-receptor activity in breast cancer cells
has been associated with increased SOX9 expression,
although this study occurs in the context of estrogen
deprivation.43
It would be interesting to observe the long-term effects
of ATRX deletion on oncogenic KRAS-mediated PDAC for-
mation. Because of the prevalence of tumors developing in
the oral mucosa, we were forced to kill MKA mice before
overt PDAC development. These tumors likely arise because
of the expression of Mist1creERT in other tissues, and we
are currently generating AtrxﬂD18/ ﬂD18 mice with a
pancreas-speciﬁc inducible cre-recombinase, which will
allow for longer-term analysis. It is possible that having only
a single copy of Mist1 contributes to the Mist1creERT/þ
AtrxﬂD18 and MKA phenotypes. Although previous studies44
and unpublished work from our laboratory demonstrated
no difference in the phenotype between mice heterozygous
or wild-type (WT) for MIST1 expression, using a different
cre-recombinase (such as Ptf1acreERT) would rule out any
contribution of Mist1 haploinsufﬁciency to the results
observed in this study.
In summary, we identiﬁed that loss of ATRX enhanced
pancreatic injury and susceptibility to KRAS-mediated
pancreatic damage. Potential gender-speciﬁc factors within
AtrxﬂD18/ ﬂD18 mice (including hormonal factors or increased
inﬂammation) provide an additional driving factor for KRAS
activity and pancreatic damage, leading to a female-speciﬁc
phenotype.
Materials and Methods
Animal Generation and Cre Induction
Mouse experiments were approved by the Animal Care
and Use Committee at Western University (Protocol #2017-
001). All mice used in this study were maintained in a C57Bl6
background. Mice expressing creERT from the Mist1 locus
(Mist1creERT/þ)5 were crossed with mice harboring an Atrx
allele with exon 18 ﬂanked by loxP sites,23 producing
male (Mist1creERT/þAtrxﬂD18/y) and female (Mist1creERT/þ
AtrxﬂD18/ﬂ D18) mice, collectively referred to as Mist1creERT/þ
AtrxﬂD18. Mist1creERT/þAtrxﬂD18 mice were crossed to mice
containing an inducible oncogenic KRAS (loxP-STOP-loxP
(LSL)-KRASG12D)45 to produce Mist1creERT/þKrasLSL-G12D/þ
AtrxﬂD18 mice (referred to as MKA). Furthermore, female
mice containing one (Mist1creERT/þAtrxﬂD18/x) or two (Mis-
t1creERT/þAtrxx/x) copies of the Atrx allele showed no obvious
phenotypic differences and were combined as a single
Mist1creERT/þ control group. Female mice expressing
KRASG12D that were heterozygous (Mist1creERT/þKrasLSL-G12D/þ
AtrxﬂD18/x) or homozygous for Atrx (Mist1creERT/þKrasLSL-G12D/þ
Atrxx/x) also showed no obvious morphologic differences
and were collectively referred to as Mist1creERT/þ
KrasLSL-G12D/þ mice.
Tamoxifen (Sigma-Aldrich, St Louis, MO; cat. #T5648)
was administered through oral gavage (2 mg/mouse) 3
times over 5 days. This resulted in >95% recombination in
acinar cells and no recombination in duct cells.24 Mice were
monitored for 60 days from ﬁrst tamoxifen gavage, and
body weight was measured weekly.
Figure 7. Gross morphology does not reveal signiﬁcant differences on dissection. Mist1creERT/þ (WT), Mist1creERT/
þAtrxﬂD18 (AtrxﬂD18), Mist1creERT/þKrasLSL-G12D/þ (KrasLSL-G12D/þ), or MKA mice. Although female MKA mice may show some
edema, the only easily identiﬁed difference is splenomegaly (*), which consistently appeared inMist1creERT/þKrasLSL-G12D/þ and
MKA mice.
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Cerulein Induced Pancreatitis
To induce recurrent pancreatic injury, control
(Mist1creERT/þ) and Mist1creERT/þAtrxﬂD18 mice were given
intraperitoneal injections of saline or cerulein (75 mg/kg
body weight; Sigma-Aldrich; cat. #C9026) twice daily for
11 days, followed by a 3-day recovery period. Mice were
weighed daily throughout the injury protocol. Mice
were killed and processed for histologic, molecular,
biochemical, and blood serum analysis.46 Serum amylase
was quantiﬁed by using Phadebas tablets (Magle Life Sci-
ences, Lund, Sweden; cat. #1302) following manufacturer’s
instructions.
Histology, Immunohistochemistry, and
Immunoﬂuorescent Analysis
The head of the pancreas was used for parafﬁn sections,
and cryostat sections were obtained from the middle
portion of pancreas. Tissue was washed 2 times in
phosphate-buffered saline and then dehydrated through a
series of alcohol washes for embedding into parafﬁn.
Parafﬁn sections (5 mm) were stained by using standard
H&E, Alcian blue (Mucin Stain; Abcam Inc, Cambridge, MA;
cat. #ab150662) or Masson’s trichrome stain (Abcam Inc;
cat. #ab150686) protocols. Sections were imaged by using
the Aperio CS2 Digital Scanner and Aperio ImageScope
software (Leica Biosystems Imaging Inc, San Diego, CA).
Total tissue area was quantiﬁed by using the Fiji software,47
and area of damage was quantiﬁed as a percentage of total
area. Levels of pancreatic damage were assessed by using a
grading scale based on 3 factors: ﬁbrosis, inﬂammation, and
presence of acinar to ductal metaplasia. Tissue sections
were scored by multiple individuals blinded to mouse
genotypes on a scale from 0 to 4. Descriptions of each score
can be found in Table 1 along with a description of scoring
PanIN lesions.
For immunohistochemical analysis, parafﬁn tissue sec-
tions were stained by using the ABC staining system (Santa
Cruz Biotechnology Inc, Dallas, TX) or the VectaStain ABC
HRP kit with ImmPACT DAB Peroxidase (HRP) Substrate
(Vector Laboratories, Brockville, ON, Canada; cat. #SK-4105)
according to kit instructions. Cleaved caspase-3 (rabbit
1:100; Cell Signaling Technology, Danvers, MA; cat.
#966455) staining was completed by using the Ventana
Discovery Ultra XT autostainer (Ventana Medical Systems
Inc, Tucson, AZ). Primary antibodies used are speciﬁc to
ATRX (rabbit; diluted 1:100 in 1.5% mouse blocking serum
in phosphate-buffered saline; Santa Cruz Biotechnology Inc;
cat. #sc15408), PDX1 (rabbit; 1:1000; Abcam Inc; cat.
#ab47267), Ki67 (rabbit 1:500; Abcam Inc; cat. #ab15580).
For immunoﬂuorescence, cryostat sections were processed
Figure 8. Loss of ATRX enhances KRASG12D’s ability to
promote pre-cancerous lesions in female mice. (A) H&E
images of pancreatic tissue from male and female Mis-
t1creERT/þ (WT), Mist1creERT/þAtrxﬂD18 (AtrxﬂD18), Mist1creERT/
þKrasLSL-G12D/þ (KrasLSL-G12D/þ), and MKA mice 60 days after
tamoxifen treatment. Arrows indicate focal ADM or PanIN
lesions. Dotted white line delineates signiﬁcant lesion area
from acinar tissue. Islets are indicated by I. Magniﬁcation
bar ¼ 200 mm. (B) Average percentage of lobules containing
at least one instance of ADM, PanIN1, or PanIN2 in KrasLSL-
G12D/þ (n ¼ 7 male or 10 female) and MKA (n ¼ 10 male or 6
female) mice. Data were assessed by using 2-way ANOVA
with Tukey post hoc test. Representative examples of ADM,
PanIN1, and PanIN2 lesions from female MKA mice. Magni-
ﬁcation bars ¼ 50 mm.
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Figure 9. Histology of pancreatic tissue after Atrx deletion. Representative (A) trichrome or (B) Alcian blue images of
pancreatic tissue from male and female Mist1creERT/þ (WT), Mist1creERT/þAtrxﬂD18 (AtrxﬂD18), Mist1creERT/þKrasLSL-G12D/þ
(KrasLSL-G12D/þ), and MKA mice 60 days after tamoxifen treatment. Increased tissue ﬁbrosis was routinely observed in MKA
females (arrows). Magniﬁcation bar ¼ 200 mm. Increased ﬁbrosis (open arrow) and duct metaplasia are observed in female
MKA tissue. Quantiﬁcation of (C) damaged area as percentage of total pancreatic area based on appearance of PanINs or
ﬁbrosis, or (D) number of ADM and PanINs (lesions) observed within Mist1creERT/þ (WT; n ¼ 8 male or 5 female), Mist1creERT/
þAtrxﬂD18 (AtrxﬂD18; n ¼ 8 male or 5 female), Mist1creERT/þKrasLSL-G12D/þ (KrasLSL-G12D/þ; n ¼ 7 male or 10 female), and MKA
(n ¼ 10 male or 6 female) mice 60 days after tamoxifen treatment. Number of ADM and PanINs (lesions) was signiﬁcantly
increased inMKA females compared with all other groups except maleMist1creERT/þKrasLSL-G12D/þ (KrasLSL-G12D/þ) mice. Data
were assessed by using 2-way ANOVA with Tukey post hoc test. Bars represent mean ± standard error; *P < .05.
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as previously described.46 Primary antibodies used were
speciﬁc to ATRX (rabbit; diluted 1:100 in blocking solution;
Santa Cruz Biotechnology Inc), MIST1 (rabbit; 1:500),48
b-catenin (mouse; 1:500; BD Biosciences, Mississauga, ON,
Canada; cat. #610153, lot#5121508), SOX9 (rabbit; 1:500;
MilliporeSigma, Etobicoke, ON, Canada; cat. #AB5535,
lot#3018860), insulin (mouse 1:500; Sigma; cat. #I2018;
lot#092K4841), or gH2AX (rabbit; 1:200; Santa Cruz
Biotechnology Inc; cat. #sc-101696, lot#12613). Secondary
antibodies used include anti-rabbit FITC (cat. #111-545-
003, lot#125266) and anti-mouse FITC (cat. #115-025-003,
lot#125278; 1:250; Jackson ImmunoResearch, West Grove,
PA). Sections were counterstained with 4’,6-diamidino-2-
phenylindole and imaged using a Leica DM5500B micro-
scope with LAS V4.4 software (Leica Microsystems Ltd,
Wetzlar, Germany).
Protein Isolation and Western Blot Analyses
Protein was isolated from the middle portion of the
pancreata and homogenized on ice using a Potter Elvehiem
Homogenizer in extraction buffer (50 mmol/L Tris [pH 7.2],
5 mmol/L MgCl2, 1 mmol/L CaCl2, 1% NP-40, 0.5 mmol/L
DTT, 0.5 mmol/L PMSF, 10 mmol/L NaF, 2 mmol/L NaVO4,
150 nmol/L aprotinin, 10 mmol/L, pepstatin, 50 mmol/L
leupeptin).46 Homogenates were sonicated for 20 seconds
on ice (level 4 Fisher Sonic Dismemberator) and centrifuged
10 minutes at 4C at 14,000g. Supernatants were taken
and frozen at –80C until used. Isolated protein was
resolved by sodium dodecylsulfate–gel electrophoresis in
10% acrylamide gels and transferred to a polyvinylidene
diﬂuoride membrane (Bio-Rad; cat. #162-0177) for Western
blot analyses.48 Primary antibodies were speciﬁc for total
MAPK (tERK1/2) (rabbit 1:2500 in 5% BSA-0.1%
Tween20; Cell Signaling Technology; cat. #9102, lot
#26), carboxypeptidase (CPA) (rabbit 1:1000 in 5%
NFDM; R&D Systems, Minneapolis, MN; cat. #AF2765, lot
#wo00117071), and amylase (rabbit 1:1000 in 5% NFDM;
Abcam; cat. #ab21156). After overnight incubation, blots
were incubated in secondary antibody (anti-rabbit HRP,
1:10,000; Jackson Labs, Bar Harbor, ME; cat. #111-035-
144) diluted in 5% NFDM for 1 hour at room temperature.
Blots were developed by using Clarity Western blot ECL
kit (Biorad; cat. #1705061) and visualized by using the
VersaDoc system with Quantity One 1-D analysis software
(Bio-Rad).
TUNEL Assay
To assess apoptosis, cryostat sections were processed
using the In Situ Cell Death detection kit (Roche, Laval, QC,
Canada; cat. #11684795910) per manufacturer’s directions.
Sections were counterstained with DAPI. The number of
TUNEL-positive cells was quantiﬁed using 7 random ﬁelds
Table 3.Morphometric Analysis of Pancreatic Tissue 60 Days After Activation of KRASG12D and Loss of Atrx
Mist1creERT/þ Mist1creERT/þAtrxﬂD18 Mist1creERT/þKrasLSL-G12D/þ MKA
Male (8) Female (5) Male (8) Female (5) Male (7) Female (10) Male (10) Female (6)
Fibrosis 0 ± 0 0 ± 0 0 ± 0 0 ± 0 1 ± 0.66 0.7 ± 0.47 0 ± 0 1.83 ± 0.48
Inﬂammation 0 ± 0 0 ± 0 0.14 ± 0.14 0.33 ± 0.21 1 ± 0.54 1 ± 0.52 0.2 ± 0.13 2.17 ± 0.70
ADM 0 ± 0 0.2 ± 0.2 0 ± 0 0 ± 0 1.57 ± 0.65 1.5 ± 0.45 0.4 ± 0.16 3 ± 0.45
Total 0 ± 0a 0.2 ± 0.2a 0.14 ± 0.14a 0.33 ± 0.21a 3.57 ± 1.8a,b 3.2 ± 1.4a,b 0.6 ± 0.27a 7 ± 1.57b
NOTE. (#) indicates n value; see methodology for scoring. Histopathologic assessment of pancreatic damage, as indicated by
3 factors: ﬁbrosis, inﬂammation, and presence of ADM. Scores are represented on a grading scale from 0 to 4. Superscript
letters “a” and “b” indicate groups that are statistically different (P < .01). Data were assessed using 2-way ANOVA and Tukey
post hoc test.
Table 4.Classiﬁcation of ADM and PanIN Lesions 60 Days After Activation of KRASG12D and Loss of Atrx
Percent of lobules determined by highest lesion grade
Genotype Sex Normal ADM PanIN1 PanIN2
KRASLSL-G12D Male (7) 83.1 ± 7.8 10.8 ± 4.2 4.9 ± 3.6 1.3 ± 1.3
Female (10) 60.1 ± 8.2 33.3 ± 6.3 6.5 ± 3.5 0 ± 0
MKA Male (10) 81.2 ± 7.8 18.8 ± 7.8 0 ± 0 0 ± 0
Female (6) 46.9 ± 11.9a 25.2 ± 5.7 16.2 ± 8.3b 11.7 ± 6.3a
NOTE. (#) indicates n values. Data were assessed using 2-way ANOVA and Tukey post hoc test. These data are presented in
Figure 8B.
aDifference from all other groups (P < .05).
bDifference from male MKA mice (P < .05).
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Figure 10. PanIN lesions in Mist1creERT/DAtrxﬂD18 mice are derived from ATRX– acinar cells undergoing ADM. (A)
Immunoﬂuorescent images for SOX9 in male and female Mist1creERT/þ (WT), Mist1creERT/þAtrxﬂD18 (AtrxﬂD18), Mist1creERT/
þKrasLSL-G12D/þ (KrasLSL-G12D/þ), andMKAmice 60 days after tamoxifen treatment. Insets show nuclear localization of SOX9 in
putative ADM in MKA mice. (B) Co-immunoﬂuorescence of putative ADM in female MKA pancreatic tissue shows SOX9
nuclear accumulation in proliferating cells based on Ki67 accumulation (red). White arrows indicate cells expressing Ki67 and
SOX9. Sections were counterstained for DAPI. Magniﬁcation bars ¼ 50 mm. (C) Quantiﬁcation of Ki67þ acinar cells in Mis-
t1creERT/þ, Mist1creERT/þAtrxﬂD18, Mist1creERT/þKrasLSL-G12D/þ, and MKA mice. Bars represent mean ± standard error. N ¼ 3 for
each group. (D) Immunohistochemistry for ATRX in putative ADM and PanINs in male and female Mist1creERT/þKrasLSL-G12D/þ
(KrasLSL-G12D/þ) andMKAmice. ATRXþ lesions are identiﬁed inMist1creERT/þKrasLSL-G12D/þmice (black arrow), whereas female
MKA revealed both ATRXþ (*) and ATRX– (**) cells within the PanINs. ATRXþ cells are found in ducts (D) and islets (I) of MKA
males and in interstitial ﬁbroblasts in MKA females. (E) Quantiﬁcation of lesions with at least 1 ATRXþ cell (black) or no ATRXþ
cells (gray) in Mist1creERT/þ (WT; n ¼ 3 for male and female), Mist1creERT/þAtrxﬂD18 (AtrxﬂD18; n ¼ 3 for male and female),
Mist1creERT/þKrasLSL-G12D/þ (KrasLSL-G12D/þ; n ¼ 3 for male or n ¼ 6 for female), and MKA (n ¼ 4 for male or n ¼ 3 for female)
mice. Bars represent mean % ± standard error.
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of view from each mouse and calculated as percentage of
TUNEL-positive cells compared with DAPI counts.
Statistical Analysis
In all cases, data were analyzed for signiﬁcance by using
an unpaired, two-tailed t test or 2-way analysis of variance
(ANOVA) with Tukey post hoc test. Values are depicted as
means ± standard error of the mean. Signiﬁcance is
considered P < .05.
References
1. Hingorani SR, Wang L, Multani AS, Combs C,
Deramaudt TB, Hruban RH, Rustgi AK, Chang S,
Tuveson DA. Trp53R172H and KrasG12D cooperate to
promote chromosomal instability and widely metastatic
pancreatic ductal adenocarcinoma in mice. Cancer Cell
2005;7:469–483.
2. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF.
Acinar cells contribute to the molecular heterogeneity of
pancreatic intraepithelial neoplasia. Am J Pathol 2007;
171:263–273.
3. Morris JPt, Cano DA, Sekine S, Wang SC, Hebrok M.
Beta-catenin blocks Kras-dependent reprogramming of
acini into pancreatic cancer precursor lesions in mice.
J Clin Invest 2010;120:508–520.
4. Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL,
Morris JP, Pan FC, Akiyama H, Wright CV, Jensen K,
Hebrok M, Sander M. Identiﬁcation of Sox9-dependent
acinar-to-ductal reprogramming as the principal mech-
anism for initiation of pancreatic ductal adenocarcinoma.
Cancer Cell 2012;22:737–750.
5. Shi G, Direnzo D, Qu C, Barney D, Miley D,
Konieczny SF. Maintenance of acinar cell organization is
critical to preventing Kras-induced acinar-ductal meta-
plasia. Oncogene 2013;32:
1950–1958.
6. Bardeesy N, Aguirre AJ, Chu GC, Cheng KH, Lopez LV,
Hezel AF, Feng B, Brennan C, Weissleder R,
Mahmood U, Hanahan D, Redston MS, Chin L,
Depinho RA. Both p16(Ink4a) and the p19(Arf)-p53
pathway constrain progression of pancreatic adenocar-
cinoma in the mouse. Proc Natl Acad Sci U S A 2006;
103:5947–5952.
7. De La OJ, Emerson LL, Goodman JL, Froebe SC,
Illum BE, Curtis AB, Murtaugh LC. Notch and Kras
reprogram pancreatic acinar cells to ductal intraepithelial
neoplasia. Proc Natl Acad Sci U S A 2008;
105:18907–18912.
8. Bailey P, Chang DK, Nones K, Johns AL, Patch AM,
Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC,
Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S,
Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O,
Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F,
Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N,
Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L,
Figure 11. Mutation anal-
ysis on PDAC patients
based on data from the
International Cancer
Genome Consortium. (A)
Comparison of gender
breakdown for all PDAC
cases, or for mutations in
ATRX, known driver muta-
tions for PDAC (KRAS,
CDNK2/P16), or for DAXX.
Impact ATRX mutations
refer to those mutations
that occur with the protein
coding region and are
predicted to have a nega-
tive impact on protein
function. (B and C) Chi-
squared analyses deter-
mining if ATRX mutations
and sex are independent
variables in PDAC (B) or
pancreatic neuroendocrine
tumors (PNETs; C).
110 Young et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 1
Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M,
Cowley MJ, Jones MD, Colvin EK, Nagrial AM,
Humphrey ES, Chantrill LA, Mawson A, Humphris J,
Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-
Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA,
Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A,
Zeps N, Moran-Jones K, Jamieson NB, Graham JS,
Duthie F, Oien K, Hair J, Grutzmann R, Maitra A,
Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA,
Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P,
Salvia R, Tortora G, Mukhopadhyay D, Petersen GM,
Australian Pancreatic Cancer Genome, Munzy DM,
Fisher WE, Karim SA, Eshleman JR, Hruban RH,
Pilarsky C, Morton JP, Sansom OJ, Scarpa A,
Musgrove EA, Bailey UH, Hofmann O, Sutherland RL,
Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N,
Biankin AV, Grimmond SM. Genomic analyses identify
molecular subtypes of pancreatic cancer. Nature 2016;
531:47–52.
9. von Figura G, Fukuda A, Roy N, Liku ME, Morris JP,
Kim GE, Russ HA, Firpo MA, Mulvihill SJ, Dawson DW,
Ferrer J, Mueller WF, Busch A, Hertel KJ, Hebrok M. The
chromatin regulator Brg1 suppresses formation of intra-
ductal papillary mucinous neoplasm and pancreatic
ductal adenocarcinoma. Nat Cell Biol 2014;16:255–267.
10. Bednar F, Schoﬁeld HK, Collins MA, Yan W, Zhang Y,
Shyam N, Eberle JA, Almada LL, Olive KP, Bardeesy N,
Fernandez-Zapico ME, Nakada D, Simeone DM,
Morrison SJ, Pasca di Magliano M. Bmi1 is required for
the initiation of pancreatic cancer through an Ink4a-
independent mechanism. Carcinogenesis 2015;
36:730–738.
11. Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD.
Daxx is an H3.3-speciﬁc histone chaperone and co-
operates with ATRX in replication-independent chro-
matin assembly at telomeres. Proc Natl Acad Sci U S A
2010;107:14075–14080.
12. Goldberg AD, Banaszynski LA, Noh KM, Lewis PW,
Elsaesser SJ, Stadler S, Dewell S, Law M, Guo X, Li X,
Wen D, Chapgier A, DeKelver RC, Miller JC, Lee YL,
Boydston EA, Holmes MC, Gregory PD, Greally JM,
Raﬁi S, Yang C, Scambler PJ, Garrick D, Gibbons RJ,
Higgs DR, Cristea IM, Urnov FD, Zheng D, Allis CD.
Distinct factors control histone variant H3.3 localization
at speciﬁc genomic regions. Cell 2010;140:678–691.
13. Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J,
de Lange T, De S, Petrini JH, Sung PA, Jasin M,
Rosenbluh J, Zwang Y, Weir BA, Hatton C, Ivanova E,
Macconaill L, Hanna M, Hahn WC, Lue NF, Reddel RR,
Jiao Y, Kinzler K, Vogelstein B, Papadopoulos N,
Meeker AK; Consortium ALTSC. Loss of ATRX, genome
instability, and an altered DNA damage response are
hallmarks of the alternative lengthening of telomeres
pathway. PLoS Genet 2012;8:e1002772.
14. Clynes D, Jelinska C, Xella B, Ayyub H, Taylor S,
Mitson M, Bachrati CZ, Higgs DR, Gibbons RJ. ATRX
dysfunction induces replication defects in primary mouse
cells. PLoS One 2014;9:e92915.
15. Levy MA, Kernohan KD, Jiang Y, Berube NG. ATRX
promotes gene expression by facilitating transcriptional
elongation through guanine-rich coding regions. Hum
Mol Genet 2015;24:1824–1835.
16. Law MJ, Lower KM, Voon HP, Hughes JR, Garrick D,
Viprakasit V, Mitson M, De Gobbi M, Marra M, Morris A,
Abbott A, Wilder SP, Taylor S, Santos GM, Cross J,
Ayyub H, Jones S, Ragoussis J, Rhodes D, Dunham I,
Higgs DR, Gibbons RJ. ATR-X syndrome protein targets
tandem repeats and inﬂuences allele-speciﬁc expression
in a size-dependent manner. Cell 2010;143:367–378.
17. Garrick D, Sharpe JA, Arkell R, Dobbie L, Smith AJ,
Wood WG, Higgs DR, Gibbons RJ. Loss of Atrx
affects trophoblast development and the pattern of
X-inactivation in extraembryonic tissues. PLoS Genet
2006;2:e58.
18. Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations
in a putative global transcriptional regulator cause X-
linked mental retardation with alpha-thalassemia (ATR-X
syndrome). Cell 1995;80:837–845.
19. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A,
Schulick RD, Tang LH, Wolfgang CL, Choti MA,
Velculescu VE, Diaz LA, Vogelstein B, Kinzler KW,
Hruban RH, Papadopoulos N. DAXX/ATRX, MEN1, and
mTOR pathway genes are frequently altered in pancreatic
neuroendocrine tumors. Science 2011;331:1199–1203.
20. Singhi AD, Liu TC, Roncaioli JL, Cao D, Zeh HJ,
Zureikat AH, Tsung A, Marsh JW, Lee KK, Hogg ME,
Bahary N, Brand RE, McGrath KM, Slivka A,
Cressman KL, Fuhrer K, O’Sullivan RJ. Alternative
lengthening of telomeres and loss of DAXX/ATRX
expression predicts metastatic disease and poor survival
in patients with pancreatic neuroendocrine tumors. Clin
Cancer Res 2017;23:600–609.
21. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J,
Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT.
Whole-exome sequencing identiﬁes ATRX mutation as a
key molecular determinant in lower-grade glioma.
Oncotarget 2012;3:1194–1203.
22. Koschmann C, Lowenstein PR, Castro MG. ATRX
mutations and glioblastoma: impaired DNA damage
repair, alternative lengthening of telomeres, and genetic
instability. Mol Cell Oncol 2016;3:e1167158.
23. Berube NG, Mangelsdorf M, Jagla M, Vanderluit J,
Garrick D, Gibbons RJ, Higgs DR, Slack RS, Picketts DJ.
The chromatin-remodeling protein ATRX is critical for
neuronal survival during corticogenesis. J Clin Invest
2005;115:258–267.
24. Johnson CL, Peat JM, Volante SN, Wang R, McLean CA,
Pin CL. Activation of protein kinase C delta leads to
increased pancreatic acinar cell de-differentiation in the
absence of MIST1. J Pathol 2012;228:351–365.
25. Shi G, Zhu L, Sun Y, Bettencourt R, Damsz B,
Hruban RH, Konieczny SF. Loss of the acinar-restricted
transcription factor Mist1 accelerates Kras-induced
pancreatic intraepithelial neoplasia. Gastroenterology
2009;136:1368–1378.
26. Garrick D, Samara V, McDowell TL, Smith AJ, Dobbie L,
Higgs DR, Gibbons RJ. A conserved truncated isoform
of the ATR-X syndrome protein lacking the SWI/SNF-
homology domain. Gene 2004;326:23–34.
2019 Female Susceptibility to KRASG12D in ATRX-Null Mice 111
27. Ritchie K, Seah C, Moulin J, Isaac C, Dick F, Berube NG.
Loss of ATRX leads to chromosome cohesion and con-
gression defects. J Cell Biol 2008;180:315–324.
28. Prevot PP, Simion A, Grimont A, Colletti M, Khalaileh A,
Van den Steen G, Sempoux C, Xu X, Roelants V, Hald J,
Bertrand L, Heimberg H, Konieczny SF, Dor Y,
Lemaigre FP, Jacquemin P. Role of the
ductal transcription factors HNF6 and Sox9 in
pancreatic acinar-to-ductal metaplasia. Gut 2012;
61:1723–1732.
29. Martinelli P, Madriles F, Canamero M, Pau EC, Pozo ND,
Guerra C, Real FX. The acinar regulator Gata6 sup-
presses KrasG12V-driven pancreatic tumorigenesis in
mice. Gut 2016;65:476–486.
30. Ledda-Columbano GM, Perra A, Pibiri M, Molotzu F,
Columbano A. Induction of pancreatic acinar cell prolif-
eration by thyroid hormone. J Endocrinol 2005;
185:393–399.
31. Hess DA, Humphrey SE, Ishibashi J, Damsz B, Lee AH,
Glimcher LH, Konieczny SF. Extensive pancreas regen-
eration following acinar-speciﬁc disruption of Xbp1 in
mice. Gastroenterology 2011;141:1463–1472.
32. Roy N, Takeuchi KK, Ruggeri JM, Bailey P, Chang D, Li J,
Leonhardt L, Puri S, Hoffman MT, Gao S, Halbrook CJ,
Song Y, Ljungman M, Malik S, Wright CV, Dawson DW,
Biankin AV, Hebrok M, Crawford HC. PDX1 dynamically
regulates pancreatic ductal adenocarcinoma initiation
and maintenance. Genes Dev 2016;30:2669–2683.
33. Mallen-St Clair J, Soydaner-Azeloglu R, Lee KE, Taylor L,
Livanos A, Pylayeva-Gupta Y, Miller G, Margueron R,
Reinberg D, Bar-Sagi D. EZH2 couples pancreatic
regeneration to neoplastic progression. Genes Dev 2012;
26:439–444.
34. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ,
Verdaguer L, Perez-Gallego L, Dubus P, Sandgren EP,
Barbacid M. Chronic pancreatitis is essential for induc-
tion of pancreatic ductal adenocarcinoma by K-Ras
oncogenes in adult mice. Cancer Cell 2007;11:291–302.
35. de Wilde RF, Heaphy CM, Maitra A, Meeker AK, Edil BH,
Wolfgang CL, Ellison TA, Schulick RD, Molenaar IQ,
Valk GD, Vriens MR, Borel Rinkes IH, Offerhaus GJ,
Hruban RH, Matsukuma KE. Loss of ATRX or DAXX
expression and concomitant acquisition of the alternative
lengthening of telomeres phenotype are late events in a
small subset of MEN-1 syndrome pancreatic neuroen-
docrine tumors. Mod Pathol 2012;25:1033–1039.
36. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH,
Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG,
Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA,
He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK,
Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH,
Maitra A, Papadopoulos N, Meeker AK. Altered
telomeres in tumors with ATRX and DAXX mutations.
Science 2011;333:425.
37. van Heek T, Rader AE, Offerhaus GJ, McCarthy DM,
Goggins M, Hruban RH, Wilentz RE. K-ras, p53, and
DPC4 (MAD4) alterations in ﬁne-needle aspirates of the
pancreas: a molecular panel correlates with and sup-
plements cytologic diagnosis. Am J Clin Pathol 2002;
117:755–765.
38. Cardoso C, Timsit S, Villard L, Khrestchatisky M,
Fontes M, Colleaux L. Speciﬁc interaction between the
XNP/ATR-X gene product and the SET domain of the
human EZH2 protein. Hum Mol Genet 1998;7:679–684.
39. Nussler NC, Reinbacher K, Shanny N, Schirmeier A,
Glanemann M, Neuhaus P, Nussler AK, Kirschner M.
Sex-speciﬁc differences in the expression levels of es-
trogen receptor subtypes in colorectal cancer. Gend Med
2008;5:209–217.
40. Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S,
Cruz-Monserrate Z, Wang H, Ji B, Logsdon CD. An NF-
kappaB pathway-mediated positive feedback loop am-
pliﬁes Ras activity to pathological levels in mice. J Clin
Invest 2012;122:1519–1528.
41. Baumgart S, Chen NM, Siveke JT, Konig A, Zhang JS,
Singh SK, Wolf E, Bartkuhn M, Esposito I, Hessmann E,
Reinecke J, Nikorowitsch J, Brunner M, Singh G,
Fernandez-Zapico ME, Smyrk T, Bamlet WR, Eilers M,
Neesse A, Gress TM, Billadeau DD, Tuveson D,
Urrutia R, Ellenrieder V. Inﬂammation-induced NFATc1-
STAT3 transcription complex promotes pancreatic
cancer initiation by KrasG12D. Cancer Discov 2014;
4:688–701.
42. Akiyama H, Stadler HS, Martin JF, Ishii TM, Beachy PA,
Nakamura T, de Crombrugghe B. Misexpression of Sox9
in mouse limb bud mesenchyme induces polydactyly
and rescues hypodactyly mice. Matrix Biology 2007;
26:224–233.
43. Jeselsohn R, Cornwell M, Pun M, Buchwalter G,
Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C,
Fu X, Nardone A, De Angelis C, Detre S, Dodson A,
Mohammed H, Carroll JS, Bowden M, Rao P, Long HW,
Li F, Dowsett M, Schiff R, Brown M. Embryonic tran-
scription factor SOX9 drives breast cancer endocrine
resistance. PNAS 2017;114:E4482–E4491.
44. Karki A, Humphrey SE, Steele RE, Karki A, Humphrey SE,
Steele RE, Hess DA, Taparowsky EJ, Konieczny SF.
Silencing Mist1 gene expression is essential for
recovery from acute pancreatitis. PLoS One 2015;
10:e0145724.
45. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D,
Montoya R, Jacks T, Tuveson DA. Analysis of lung tumor
initiation and progression using conditional expression of
K-ras. Genes Develop 2001;15:3243–3248.
46. Fazio EN, Young CC, Toma J, Levy M, Berger KR,
Johnson CL, Mehmood R, Swan P, Chu A, Cregan SP,
Dilworth FJ, Howlett CJ, Pin CL. Activating transcription
factor 3 promotes loss of the acinar cell phenotype in
response to cerulein-induced pancreatitis in mice. Mol
Biol Cell 2017;28:2347–2359.
47. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V,
Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S,
Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K,
Tomancak P, Cardona A. Fiji: an open-source platform
for biological-image analysis. Nat Methods 2012;
9:676–682.
48. Pin CL, Bonvissuto AC, Konieczny SF. Mist1
expression is a common link among serous exocrine
cells exhibiting regulated exocytosis. Anat Rec 2000;
259:157–167.
112 Young et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 1
Received February 28, 2018. Accepted September 6, 2018.
Correspondence
Address correspondence to: Christopher Pin, PhD, Department of Paediatrics,
University of Western Ontario, Children’s Health Research Institute, 5th Floor,
Victoria Research Laboratories, London, Ontario, Canada N6C 2V5. e-mail:
cpin@uwo.ca; fax: (519) 685-8186.
Author contributions
CY: acquisition of data, analysis and interpretation of data, drafting of
the manuscript; RB: acquisition of data, analysis and interpretation of data;
CH: analysis and interpretation of data; TH: acquisition of data; JH:
acquisition of data; DH: material support; RG: material support;
HC: acquisition of data, analysis and interpretation of data, critical revision of
the manuscript for important intellectual content; AB: critical revision of the
manuscript for important intellectual content; CP: study concept and design,
drafting of the manuscript, critical revision of the manuscript for important
intellectual content, obtained funding, study supervision.
Conﬂicts of interest
The authors disclose no conﬂicts.
Funding
Funding was provided to C.P. by the Rob Lutterman Memorial Foundation and
Cancer Research Society of Canada. C.Y. was funded by a Canadian Graduate
Scholarship. R.B. received a Canadian Association of Gastroenterology
summer scholarship.
2019 Female Susceptibility to KRASG12D in ATRX-Null Mice 113
